Clinical Trial Update: Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This document provides an update on an ongoing Phase 1/Phase 2 clinical trial evaluating CD33-targeted CAR-T cells (CD33CART) in children and young adults with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CD33CART (Anti-CD33 chimeric antigen receptor-expressing T cells)

Snippet

Sponsor: Center for International Blood and Marrow Transplant Research | Conditions: Acute Myelogenous Leukemia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING